Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹24 Cr
Revenue (TTM)
₹87 Cr
Net Profit (TTM)
₹1 Cr
ROE
3.1 %
ROCE
6.7 %
P/E Ratio
28.1
P/B Ratio
0.8
Industry P/E
34.6
EV/EBITDA
11.1
Div. Yield
0 %
Debt to Equity
0.7
Book Value
₹37.9
EPS
₹1.1
Face value
10
Shares outstanding
7,545,056
CFO
₹8.02 Cr
EBITDA
₹21.84 Cr
Net Profit
₹7.33 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chandra Pharma
| -22.4 | -18.9 | -22.4 | -38.8 | -30.9 | -4.2 | -- |
|
BSE Healthcare*
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Chandra Pharma
| -37.5 | -40.4 | 3.6 | 25.6 | 100.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chandra Pharma
|
32.0 | 24.1 | 86.7 | 0.9 | -- | 3.1 | 28.1 | 0.8 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
2003
Chairman
Hemant Chandravadan Bhagat
Managing Director
Hemant Chandravadan Bhagat
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Chandra Bhagat Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Chandra Bhagat Pharma Ltd is ₹32.00 (BSE) as of 01-Apr-2026 IST. Chandra Bhagat Pharma Ltd has given a return of -30.9% in the last 3 years.
The P/E ratio of Chandra Bhagat Pharma Ltd is 28.15 times as on 01-Apr-2026, a 19 discount to its peers’ median range of 34.60 times.
The P/B ratio of Chandra Bhagat Pharma Ltd is 0.84 times as on 01-Apr-2026, a 73 discount to its peers’ median range of 3.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.03
|
1.38
|
|
2024
|
46.84
|
2.59
|
|
2023
|
80.83
|
2.85
|
|
2022
|
107.78
|
3.38
|
|
2021
|
157.34
|
1.22
|
The 52-week high and low of Chandra Bhagat Pharma Ltd are Rs 61.50 and Rs 29.95 as of 02-Apr-2026.
Chandra Bhagat Pharma Ltd has a market capitalisation of ₹ 24 Cr as on 01-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Chandra Bhagat Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹1.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.